Examkin

Soru

Zorluk: OrtaGynecologic Infections

For each patient presenting with vaginal or cervical symptoms, select the most appropriate management plan regarding antimicrobial therapy and sexual partner evaluation.

  • A 25-year-old woman presents with severe vaginal itching and a thick, cottage-cheese-like discharge. Examination reveals vulvovaginal erythema and a vaginal pH of 4.2.Administer oral fluconazole; sexual partner treatment is not routinely recommended.
  • A 30-year-old woman reports a fishy vaginal odor that worsens after intercourse. Speculum examination shows a thin, homogeneous, grayish-white discharge, and clue cells are seen on saline microscopy.Prescribe oral metronidazole; sexual partner treatment is not routinely recommended.
  • A 22-year-old woman complains of copious, frothy, yellow-green vaginal discharge and dyspareunia. Examination reveals a 'strawberry cervix' and motile organisms with flagella on wet mount.Prescribe oral metronidazole; concurrent evaluation and treatment of sexual partner(s) is required.
  • A 27-year-old woman presents with intermenstrual bleeding and dysuria. Examination shows mucopurulent discharge at the cervical os and easily induced cervical bleeding on contact, with numerous leukocytes on wet mount but no identifiable organisms.Administer intramuscular ceftriaxone and oral doxycycline; concurrent evaluation and treatment of sexual partner(s) is required.

Cevap

Vulvovaginal candidiasis matches with fluconazole (no partner treatment). Bacterial vaginosis matches with metronidazole (no partner treatment). Trichomoniasis matches with metronidazole (partner treatment required). Acute cervicitis matches with ceftriaxone and doxycycline (partner treatment required).
Each patient's clinical presentation corresponds directly to a specific gynecologic infection with clear guidelines for both the patient's pharmacotherapy and the management of their sexual partners. Distinguishing between dysbiosis (BV, VVC) which does not require partner treatment, and true STIs (trichomoniasis, cervicitis) which mandate partner treatment, is a critical clinical skill.

Adım Adım Çözüm

1
Analyze the first clinical presentation to identify the specific gynecologic condition.
Thick white discharge with intense pruritus and normal pH (4.2) indicates vulvovaginal candidiasis (VVC).
Accurate diagnosis based on symptom profile and pH is required to select appropriate pharmacotherapy.
2
Determine the treatment and partner management guidelines for VVC.
VVC requires antifungal therapy (e.g., fluconazole) but is not a sexually transmitted infection, so partner treatment is unnecessary.
Antimicrobial stewardship and current guidelines dictate not treating partners for fungal overgrowth.
3
Analyze the second presentation to identify the condition.
Thin, malodorous discharge, clue cells, and an elevated pH (5.5) are diagnostic for bacterial vaginosis (BV).
Clue cells and a positive whiff test (fishy odor) are classic Amsel criteria for BV.
4
Determine the treatment and partner management for BV.
BV is treated with metronidazole. Partner treatment has not been shown to prevent recurrence and is not recommended.
Treating male partners for BV does not alter the clinical course for the female patient and unnecessarily exposes the partner to antibiotics.
5
Identify the condition in the third presentation.
Frothy, yellow-green discharge, a 'strawberry cervix,' and motile organisms on wet mount indicate Trichomonas vaginalis.
Direct visualization of motile flagellated protozoa confirms trichomoniasis.
6
Establish the management protocol for Trichomoniasis.
Trichomoniasis requires systemic metronidazole. As a highly contagious STI, partner treatment is absolutely required to prevent reinfection.
Untreated partners are the primary cause of recurrent Trichomonas infections.
7
Evaluate the fourth clinical presentation.
Mucopurulent discharge, cervical friability, and numerous leukocytes without visible organisms indicate acute cervicitis (presumptive gonorrhea/chlamydia).
These findings are classic for cervical inflammation caused by intracellular or fastidious pathogens not visible on standard wet mount.
8
Determine empiric treatment for acute cervicitis.
Empiric coverage includes ceftriaxone (for N. gonorrhoeae) and doxycycline (for C. trachomatis). As these are STIs, partner evaluation and treatment are mandatory.
Immediate empiric treatment for both major pathogens is standard of care while awaiting NAAT results, along with partner therapy.

Anahtar Kavram

Differentiation of common vaginal and cervical infections by clinical presentation and their specific management protocols, particularly distinguishing when sexual partner treatment is indicated (STIs) versus when it is not (dysbiosis/overgrowth).
Bu soruyu puanla

Konular

Gynecologic Infections

Bu konudan daha fazla soru